Molecular Formula | C17H15N7O2 |
Molar Mass | 349.35 |
Density | 1.48 |
Boling Point | 642.3±65.0 °C(Predicted) |
Solubility | DMSO: soluble0.5mg/mL, clear (warmed) |
Appearance | powder |
Color | white to beige |
pKa | 0.00±0.19(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,2-8°C |
Use | CP-466722 is an effective, reversible ATM inhibitor that does not affect ATR and inhibits similar PI3K or PIKK in cells. |
In vitro study | In vitro, CP-466722 is identified as a potential inhibitor to decrease the activity of purified ATM kinase to phosphorylate GST-p53(1–101) substrate. In addition, CP-466722 also shows the inhibitory activities against abl and src kinases. In HeLa cells, CP-466722 at doses of 6μM, results in the inhibition in ATM-dependent phosphorylation by reversibly inhibiting ionizing radiation (IR)-induced ATM kinase activity. Besides, ATM-dependent p53 induction is also inhibited by CP-466722 in MCF-7 human breast cancer cells and primary and immortalized diploid human fibroblasts. In response to IR, CP-466722 increased proportion of cells with G2/M DNA content and reduces proportion of cells with G1-phase DNA content in HeLa cells. Transient exposure to CP-466722 for a period of 4 hours sensitizes HeLa cells to IR without affecting cell plating nor cell viability. |
Hazard Symbols | Xn - Harmful![]() |
Risk Codes | 22 - Harmful if swallowed |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.862 ml | 14.312 ml | 28.625 ml |
5 mM | 0.572 ml | 2.862 ml | 5.725 ml |
10 mM | 0.286 ml | 1.431 ml | 2.862 ml |
5 mM | 0.057 ml | 0.286 ml | 0.572 ml |